Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Related

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 500 million

Vinge has advised ABG Sundal Collier as arranger in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 500 million under the existing framework of SEK 2 billion.
April 24, 2026

Vinge advises GBL on its acquisition of BUKO Group

Vinge, together with Latham & Watkins, advises Groupe Bruxelles Lambert (“GBL”) (Euronext Brussels: GBLB) on its acquisition of BUKO Group, a leading platform in temporary traffic management, from funds advised by Equistone Partners Europe and the founding family, while management will re-invest alongside GBL. The transaction, which is subject to customary approvals, will entail a EUR 0.5 billion equity investment by GBL.
April 24, 2026

Vinge advise Lagercrantz Group on the business acquisition of FMK Trafikprodukter

Lagercrantz Group, through its subsidiary Nordic Road Safety, has entered into an agreement to acquire the business and assets of FMK Trafikprodukter – a niche company specialising in CE-certified road barrier systems for the Swedish and Nordic infrastructure market.
April 24, 2026